Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
AstraZeneca
Harvard Business School
McKesson
Merck

Last Updated: June 27, 2022

CLINICAL TRIALS PROFILE FOR TIVOZANIB HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tivozanib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00502307 ↗ A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma Completed AVEO Pharmaceuticals, Inc. Phase 2 2007-10-01 This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor.
NCT00563147 ↗ A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma Completed AVEO Pharmaceuticals, Inc. Phase 1 2007-11-01 The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and Toriselâ„¢ given in combination for renal cell cancer. The study will also assess the effects of the combination of tivozanib (AV-951) and Toriselâ„¢ on the tumor. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the treatment of advanced renal cell carcinoma.
NCT00660153 ↗ Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers Completed AVEO Pharmaceuticals, Inc. Phase 1 2008-06-01 The FOLFOX6 regimen is a standard chemotherapy regimen for the treatment of patients with colorectal cancer and other gastrointestinal cancers. Tivozanib (AV-951) is a targeted anti-angiogenesis agent that has demonstrated acceptable tolerability in a phase I clinical trial. This study is designed to test the hypothesis that tivozanib (AV-951) can be combined with standard FOLFOX6 chemotherapy for the treatment of patients with colorectal and other gastrointestinal cancers. The purpose of this study is to determine the maximum dose of tivozanib (AV-951) that can be safely combined with FOLFOX6 chemotherapy, and to evaluate the safety profile, tolerability, and pharmacokinetics of this combination.
NCT00717340 ↗ A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer Completed AVEO Pharmaceuticals, Inc. Phase 1 2009-02-01 This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, maximum tolerated dose, and overall response rate of tivozanib (AV-951) and paclitaxel in a breast cancer.
NCT00826878 ↗ An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC) Completed AVEO Pharmaceuticals, Inc. Phase 1 2009-01-01 This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) with this dosing schedule, as well as overall response rate of tivozanib (AV-951) administration in NSCLC.
NCT01030783 ↗ A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Completed AVEO Pharmaceuticals, Inc. Phase 3 2009-12-01 This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.
NCT01058655 ↗ RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer Completed AVEO Pharmaceuticals, Inc. Phase 1/Phase 2 2010-02-01 Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow. Vascular endothelial growth factor (VEGF) is one of the cell pathways used for this blood vessel growth. When the investigators interfere with the VEGF pathway, the investigators inhibit this blood vessel growth which is required by tumors. One of the study drugs being used, tivozanib (AV-951), selectively interferes with the VEGF pathway. The second study drug being used, everolimus (RAD001) interferes with the mTOR pathway. The mTOR pathway is another pathway involved in blood vessel and tumor cell growth. By combining these two drugs the investigators hope to slow or reverse tumor cell growth in patients whose tumors have become resistant to other therapies for their disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tivozanib Hydrochloride

Condition Name

Condition Name for Tivozanib Hydrochloride
Intervention Trials
Renal Cell Carcinoma 4
Carcinoma, Renal Cell 3
Prostate Cancer 2
Colorectal Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tivozanib Hydrochloride
Intervention Trials
Carcinoma 12
Carcinoma, Renal Cell 11
Colorectal Neoplasms 4
Carcinoma, Hepatocellular 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tivozanib Hydrochloride

Trials by Country

Trials by Country for Tivozanib Hydrochloride
Location Trials
United States 160
India 19
Canada 18
France 14
United Kingdom 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tivozanib Hydrochloride
Location Trials
Massachusetts 12
Florida 12
New York 10
Texas 10
California 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tivozanib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Tivozanib Hydrochloride
Clinical Trial Phase Trials
Phase 3 4
Phase 2 12
Phase 1/Phase 2 7
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tivozanib Hydrochloride
Clinical Trial Phase Trials
Completed 21
Terminated 5
Withdrawn 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tivozanib Hydrochloride

Sponsor Name

Sponsor Name for Tivozanib Hydrochloride
Sponsor Trials
AVEO Pharmaceuticals, Inc. 28
National Comprehensive Cancer Network 5
Massachusetts General Hospital 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tivozanib Hydrochloride
Sponsor Trials
Industry 36
Other 21
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
AstraZeneca
Dow
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.